Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Breast 1

Conditions

Breast Neoplasms 233Neoplasms 163Prostatic Neoplasms 143Colorectal Neoplasms 105Lung Neoplasms 97Leukemia, Myeloid, Acute 74Pancreatic Neoplasms 72Carcinoma, Non-Small-Cell Lung 71Multiple Myeloma 61Brain Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Melanoma 51Glioblastoma 48Carcinoma, Hepatocellular 45Ovarian Neoplasms 44Head and Neck Neoplasms 43Uterine Cervical Neoplasms 41Neoplasm Metastasis 41Sarcoma 40Glioma 39Stomach Neoplasms 37Hematologic Neoplasms 37Squamous Cell Carcinoma of Head and Neck 35Recurrence 35Lymphoma, Non-Hodgkin 34Carcinoma, Renal Cell 34Esophageal Neoplasms 33Lymphoma 32Leukemia 32Rectal Neoplasms 31

Interventions

exemestane 1Leuprolide 1Letrozole 1Goserelin 1Gonadotropin-Releasing Hormone 1Bupropion 1Aromatase Inhibitors 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Sexual Dysfunctions, Psychological × 30 days × Clear all
NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡